Products

What will AGI do for Abacavir/lamivudine/zidovudine?

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS. The first component of this combination drug is a reverse transcriptase inhibitor with the molecular formula C14H18N6O, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier WR2TIP26VS, chemically known as 2-cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-, (1s-cis)- but more generally known as abacavir, which bears U.S. National Institutes of Health Compound Identifier 65140. Abacavir most often appears in forms succinate and sulfate, and is sometimes combined with lamivudine and zidovudine. The European Medicines Agency schedules Abacavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07356MIG. The term ABACAVIR is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 11, No. 3 1997, List 38). The World Health Organization schedules abacavir in its Anatomical Therapeutic Chemical (ATC) Classification. The second component of this combination drug is a reverse transcriptase inhibitor with the molecular formula C8H11N3O3S, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 2T8Q726O95, chemically known as 4-amino-1-((2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1h)-pyrimidinone but more generally known as lamivudine, which bears U.S. National Institutes of Health Compound Identifier 60825. The European Medicines Agency schedules Lamivudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08392MIG. The term LAMIVUDINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 6, No, 3 1992, List 32). The World Health Organization schedules lamivudine in its Anatomical Therapeutic Chemical (ATC) Classification. The third component of this combination drug is a reverse transcriptase inhibitor, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 4B9XT59T7S. The European Medicines Agency schedules Zidovudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00153MIG. Zidovudine generally arises in the molecular formula C10H13N5O4. The term ZIDOVUDINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 1, no. 4, 1987, list 27.)